Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,839 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05382559RecruitingPhase 1
Study drug for advanced cancers with KRAS G12D mutation
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
Duarte, CaliforniaAges 18 years+ - NCT05413850RecruitingPhase 1/Phase 2
Lu-177 PSMA drug study for advanced prostate cancer
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
Miami, FloridaAges 18 years+ - NCT05398861RecruitingPhase 2
Testing utidelone plus bevacizumab for HER2-negative advanced breast cancer
This trial studies whether utidelone combined with bevacizumab can shrink tumors and slow progression in women with advanced HER2-negative breast cancer that has already been treated at least twice. It may help people who have limited options after earlier chemotherapy and/or hormone (endocrine) treatments.
Zhengzhou, HenanAges 18–70 - NCT05378334Recruiting
Test herbal treatment for lung cancer spread to bone
This trial studies whether the herbal medicine HGXJT can improve outcomes and safety for people with non-small cell lung cancer that has spread to the bones. It is designed for a specific lung cancer type (EGFR and ALK wild type) and people who have not had certain immune treatments before.
Guangzhou, GuangdongAges 18–75 - NCT05388773RecruitingPhase 2
Surgery then lower-dose radiation for p16+ throat cancer
This Phase 2 study tests whether removing the tumor through the mouth, followed by a reduced course of radiation, can control HPV-related (p16+) oropharynx throat cancer. It may help reduce treatment intensity after surgery, while still aiming to keep the cancer from coming back.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05404139RecruitingPhase 2
Short hormone therapy and radiation for prostate cancer that has spread a little
This trial tests a shorter course of hormone therapy plus targeted radiation for prostate cancer that has spread to a few spots (oligometastatic). The goal is to see if less hormone therapy can still control the cancer effectively.
Toronto, OntarioAges 18–100 - NCT05371132RecruitingPhase 1
PET scan study to track immune response after SBRT
This early (Phase 1) study uses a special PET scan to measure how your immune system responds after stereotactic body radiation therapy (SBRT). The goal is to see whether the scan result can serve as a marker of immune response, which may help future treatment planning.
Duarte, CaliforniaAges 18 years+ - NCT05315700RecruitingPhase 1/Phase 2
ORIC-114 for advanced lung or breast cancers with EGFR or HER2 changes
This early-phase study tests ORIC-114 to treat advanced solid tumors that have certain EGFR or HER2 genetic changes, often found in lung and breast cancers. It may help by targeting those specific cancer mutations, especially when standard treatments no longer work or aren’t tolerated.
Duarte, CaliforniaAges 18 years+ - NCT05319730RecruitingPhase 1/Phase 2
Testing new drugs, with or without pembrolizumab, for advanced esophageal cancer
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
Tucson, ArizonaAges 18 years+ - NCT05332002RecruitingPhase 2
Study chemotherapy plus immunotherapy for HER2-negative esophageal cancer
This Phase 2 trial tests a combination treatment called sFOLFOXIRI for advanced esophageal or stomach-area cancer that is HER2-negative. It aims to see how well the treatment works and whether it is safe for people who have not had standard chemotherapy for this metastatic cancer yet.
Hamilton, New JerseyAges 18 years+ - NCT05358548RecruitingPhase 2
Alternating treatment for advanced lung and head-neck cancers
This Phase 2 study tests an approach that alternates treatments for advanced lung cancer or recurrent/metastatic head and neck squamous cell cancer. It may help by improving how well the cancer responds while managing side effects differently than standard back-to-back therapy.
Elizabeth, New JerseyAges 18 years+ - NCT05327465Recruiting
Exercise program for Black men on prostate hormone therapy
This trial tests whether a structured exercise program can improve heart and blood-vessel health in Black men receiving androgen deprivation therapy for prostate cancer. It may help your cardiovascular (heart) health and monitors safety during the program.
Boston, MassachusettsAges 18 years+ - NCT05301101Recruiting
Re-irradiation planning for tumors near previously treated organs
This study tests a more personalized way to plan “re-irradiation,” meaning giving radiation again in an area that was already treated before. It aims to better calculate organ risk to reduce harmful side effects while treating cancer.
Milwaukee, WisconsinAges 18 years+ - NCT05305924RecruitingPhase 2
Fulvestrant plus abemaciclib for ER+, HER2− advanced breast cancer
This Phase 2 study tests whether adding abemaciclib to fulvestrant can slow or shrink ER-positive, HER2-negative metastatic breast cancer. It is mainly for people whose cancer has progressed despite prior treatment with a CDK4/6 inhibitor and an aromatase inhibitor.
Houston, TexasAges 18 years+ - NCT05274048RecruitingPhase 1
Neratinib plus antibody-drug for HER2-positive stomach or esophagus cancer
This early-phase trial tests neratinib together with an antibody-drug to treat advanced HER2-positive gastro-esophageal (stomach/esophagus) cancer that can’t be removed by surgery. It’s for people whose cancer has progressed after at least one HER2-targeted treatment, aiming to shrink tumors and improve outcomes.
Palo Alto, CaliforniaAges 18 years+ - NCT05296681RecruitingPhase 2
Probiotic trial to help irinotecan work better in metastatic colon cancer
This trial tests a “microbiome health” product (a probiotic-type supplement) to improve how well irinotecan chemotherapy works for people with metastatic colon cancer. It aims to support gut health so treatment can be delivered effectively.
Hamilton, New JerseyAges 18 years+ - NCT05287945RecruitingPhase 1/Phase 2
Orellanine for kidney cancer patients on dialysis
This early-stage study tests orellanine to treat advanced kidney cancer that has spread (metastatic clear-cell or papillary type). It may help by shrinking or controlling cancer, and by seeing whether the treatment is safe and tolerable in people already on chronic dialysis.
Orange, CaliforniaAges 18 years+ - NCT05306132RecruitingPhase 1
Test drug ASKC202 for advanced lung cancer and MET-positive tumors
This Phase 1 trial studies how safe ASKC202 is, what dose is tolerable, and whether it shows early signs of shrinking certain advanced cancers. Depending on your tumor type and prior treatments, ASKC202 may be tested alone or with another drug.
Zhengzhou, HenanAges 18 years+ - NCT05253651RecruitingPhase 3
Tucatinib plus trastuzumab with chemo for HER2+ metastatic colon cancer
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
Glendale, ArizonaAges 18 years+ - NCT05245136Recruiting
Blood test study for advanced cancer monitoring
This study uses a blood test (liquid biopsy) to look for tumor DNA in patients with advanced cancer. It aims to see if this test can help doctors monitor the cancer and make better treatment decisions.
Augsburg, BavariaAges 18 years+ - NCT05256745RecruitingPhase 1/Phase 2
A medicine to protect the heart during breast cancer chemotherapy
This early-phase study tests azeliragon to lower the risk of chemotherapy-related heart damage in women with early-stage breast cancer. Participants get their planned standard chemotherapy, plus the study medicine, and are monitored for safety and heart health.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05248581Recruiting
Living donor liver transplant for unresectable colon cancer spread
This trial looks at using a living donor liver transplant for people whose colon or rectal cancer has spread to the liver in a way that can’t be removed with standard surgery. It may help if you might otherwise have limited options because your liver surgery would be too risky.
Rochester, New YorkAges 18 years+ - NCT02215928Recruiting
Using tumor genetic tests to guide treatment choices
This study looks at your tumor’s genetic information to help doctors recommend treatment for cancers that have spread. It may help you get the most suitable therapy based on what’s found in your tumor.
Palo Alto, CaliforniaAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,839 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.